Baricitinib

3 articles published between August 12, 2026 and October 18, 2026.

Covered in Body and Science.

THE DRUG DOCKET

The FDA adds thrombosis and cancer to Olumiant's boxed warning

A 9 October labelling supplement folds results from two post-marketing rheumatoid-arthritis safety studies into the JAK inhibitor baricitinib's boxed warning, and revises its infection and cardiovascular sections.

3 min read

WHAT THE STUDY ACTUALLY SAYS

JAK inhibitors regrow hair in severe alopecia areata. About a third reach the endpoint

In two phase 3 trials, 38.8% and 35.9% on baricitinib 4 mg reached near-complete scalp regrowth at 36 weeks against 6.2% and 3.3% on placebo — the first drug class to do this for the condition.

4 min read

ANALYSIS

Biologics changed severe eczema. About a third of patients reach clear or near-clear skin

In the two pivotal dupilumab trials, 36% to 38% reached that endpoint at 16 weeks against 8% to 10% on placebo. A 97-trial network review finds the newer drugs clustered closely together.

4 min read

This page indexes this newspaper’s reporting on Baricitinib. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.